Laurel Habel to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications Laurel Habel has written about Antineoplastic Agents, Hormonal.
Connection Strength
1.274
-
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
Score: 0.689
-
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.129
-
Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22(3):365-73.
Score: 0.106
-
Racial and ethnic differences in adjuvant hormonal therapy use. J Womens Health (Larchmt). 2012 Sep; 21(9):950-8.
Score: 0.102
-
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
Score: 0.097
-
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
Score: 0.085
-
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8(3):R25.
Score: 0.067